1.Institute of Biochemical and Biotech Medcines, school of Pharmaceutical Science, Shandong University, Jinan 250012, China; 2.National Glycoengineering Research Center, Shangdong University, Jinan, Shandong 250012, China
Abstract��
OBJECTIVE To summarize advances in heparin nanoparticles. METHODS Literatures recently published were searched and reviewed for the structures, synthetic methods, properties and application prospects of heparin nanoparticle. RESULTS Nowadays, researches are focused on heparin-conjugated nanoparticles and nanoparticles assembled by heparin or heparin derivatives. The former can improve biocompatibility, targeting ability and drug loading capacity, while the latter were utilized in targeting transportation of protein and antitumor drugs. CONCLUSION The combination of nanoparticles and heparin may bring new possibilities for clinical applications of heparin and improve the biological capabilities of existing medicinal nanoparticles. However, a great deal of problems, such as preparation process, pharmacology and toxicology evaluation, and quality control should be resolved first.
ZHAO Na-,
,
CUI Hui-Fei- etc
.Advance of Heparin-Coated and Heparin-Based Nanoparticles[J] Chinese Pharmaceutical Journal, 2013,V48(18): 1531-1535
��
[1]
SALATA O V. Applications of nanoparticles in biology and medicine . J Nanobiotechnol, 2004, 2(1): 3-8.[2] SOPPIMATH K S, AMINABHAVI T M, KULKARNI A R, et al. Biodegradable polymeric nanoparticles as drug delivery devices . J Controlled Release, 2001, 70(1): 1-20.[3] JIN L X. Research and clinical application of nano-drug carriers. J Clin Rehabilitative Tissue Engineering Res(�й���֯�����о����ٴ�����), 2010, 14(8): 1429-1432.[4] BRIGGER I, DUBERNET C, COUVREUR P. Nanoparticles in cancer therapy and diagnosis . Adv Drug Deliv Rev, 2002, 54: 631-651.[5] DE M, GHOSH P S, ROTELLO V M. Applications of nanoparticles in biology . Adv Mater, 2008, 20(22): 4225-4241.[6] DAWES J, PEPPER D S. Catabolism of low-dose heparin in man . Thromb Res, 1979, 14(6): 845-860.[7] GARG H G, ROUGHLEY P J, HALES C A. Proteoglycans in Lung Disease. New York, Basel: Marcel Dekker Inc, 2003: 377-398.[8] HIRSH J, WARKENTIN T E, SHAUGHNESSY S G, et al. Heparin and low-molecular-weight heparin-mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest, 2001, 119(suppl 1): 64-94. [9] CAPILA I, LINHARDT R J. Heparin-protein interactions. Angew Chem Int Ed, 2002, 41(3): 390-412. WANG L, BROWN J R, VARKI A, et al. Heparin��s anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockage of L- and P-selectins . J Clin Invest, 2002, 110(1): 127-136. BORSIG L, WONG R, FERAMISCO J, et al. Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis . PNAS, 2011, 98(6): 3352-3357. VLODAVSKYA I, ILANA N, NADIRA Y, et al. Heparanase, heparin and the coagulation system in cancer progression . Thromb Res, 2007, 120(suppl 2): 112-120. YAYON A, KLAGSBRUN M, ESKO J D, et al. Cell Surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor . Cell, 1991, 64(1): 841-848. GITAY-GOREN H, SOKER S, VLODAVSKY I, et al. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules . J Biol Chem, 1992, 267(9): 6093-6098. TAO J, CHEN Y, XIONG F, et al. Magnetic nanoparticles and their application in drug delivery system . Prog Pharm Sci(ҩѧ��չ),2010, 34(4): 145-151. KE X, DENG L, CHEN J. Research progress of superparamagnetic iron oxide nanoparticles in drug delivery system. Pharm Clin Res(ҩѧ���ٴ��о�), 2011, 19(3): 257-261. KHURSHID H, KIM S H, BONDER M J, et al. Development of heparin-coated magnetic nanoparticles for targeted drug delivery applications . J Applied Physics, 2009, 105(07):308. MIN K A, YU F, YANG V C, et al. Transcellular transport of heparin-coated magnetic iron oxide nanoparticles(Hep-MION) under the influence of an applied magnetic field . Pharmaceutics,2010, 2(2): 119-135. LEE D Y. Highly effective T2 MR contrast agent based on heparinized superparamagnetic iron oxide nanoparticles . Macromolecular Res, 2011, 19(8): 843-847. YUK S H, OH K S, CHO S H, et al. Glycol chitosan/heparin immobilized iron oxide nanoparticles with a tumor-targeting characteristic for magnetic resonance imaging . Biomacromolecules,2011, 12(6): 2335-2343. HWANG J H, LEE S, KIM E, et al. Heparin-coated superparamagnetic nanoparticle-mediated adeno-associated virus delivery for enhancing cellular transduction . Int J Pharmaceut,2011, 421(2): 397- 404. JAIN P K, HUANG X H, EL-SAYED I H, et al. Noble metals on the nanoscale: Optical and photothermal properties and some applications in imaging, sensing, biology, and medicine . Accounts Chem Res, 2008, 41(12): 1578-1586 . LEE K, LEE H, BAE K H, et al. Heparin immobilized gold nanoparticles for targeted detection and apoptotic death of metastatic cancer cells . Biomaterials, 2010, 31(25): 6530-6536. CHUNG Y I, KIMA J C, KIM Y H, et al. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting . J Controlled Release, 2010, 143(3): 374-382. CHUNG Y I, TAE G, YUK S H. A facile method to prepare heparin-functionalized nanoparticles for controlled release of growth factors . Biomaterials, 2006, 27: 2621-2626. CHUNG Y I, KIMC S K, LEE Y K, et al. Efficient revascularization by VEGF administration via heparin-functionalized nanoparticle-fibrin complex . J Controlled Release, 2010, 143(3): 282-289. CHAUVIERRE C, MARDENB M C, VAUTHIER C, et al. Heparin coated poly(alkylcyanoacrylate) nanoparticles coupled to hemoglobin: A new oxygen carrier . Biomaterials, 2004, 25(15): 3081-3086. UVIERRE C, MANCHANDA R, LABARRE D, et al. Artificial oxygen carrier based on polysaccharides-poly(alkylcyanoacrylates) nanoparticle templates . Biomaterials, 2010, 31: 6069-6074. SOCHA M, BARTECKI P, PASSIRANI C, et al. Stealth nanoparticles coated with heparin as peptide or protein carriers . J Drug Targeting, 2009, 17(8): 575-585. WILEY S R, SCHOOLEY K, SMOLAK P J, et al. Identification and characterization of a new member of the TNF family that induces apoptosis . Immunity, 1995, 3(6):673-662 . KIM Y J, CHAE S Y, JIN C H, et al.In vitro characteristics of heparin/tumor necrosis factor-related apoptosis-inducing ligand nanocomplexes . Mol Cryst Liq Cryst, 2009, 508(1): 91/ -100/. ZENG H, ZHANG H, HUANG K, et al. Advances in pharmaceutical research of basic fibroblast growth factor . Chin J New Drugs(�й���ҩ��־), 2010, 19(11): 949-952. TANG D W, YU S H, HO Y C, et al. Heparinized chitosan/poly(��-glutamic acid) nanoparticles for multi-functional delivery of fibroblast growth factor and heparin . Biomaterials, 2010, 31(35): 9320-9332. PARK K H, KIM H, KUN N A. Neuronal differentiation of PC12 cells cultured on growth factor-loaded nanoparticles coated on PLGA microspheres . J Microbiol Biotechnol, 2009, 19(11): 1490-1495. MORI Y, NAKAMURA S, KISHIMOTO S, et al. Preparation and characterization of low-molecular-weight heparin/protamine nanoparticles(LMW-h/P NPs) as FGF-2 carrier . Int J Nanomedicine, 2010, 5: 147-155. MOGHIMI S M, HUNTER A C, MURRAY J C. Long-circulating and target-specific nanoparticles: Theory to practice . Pharmacol Rev, 2001, 53(2):283-318. PARK K, LEE G Y, KIM Y S, et al. Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity . J Controlled Release, 2006, 114(3): 300-306. WANG Y, XIN D C, LIU K J, et al. Heparin paclitaxel conjugates as drug delivery system: Synthesis, self-assembly property, drug release, and antitumor activity . Bioconjugate Chem, 2009, 20(12): 2214-2221. HOU L, FAN Y, YAO J, et al. Low molecular weight heparin-all-trans-retinoid acid conjugate as a drug carrier for combination cancer chemotherapy of paclitaxel and all-trans-retinoid acid . Carbohydrate Polymers, 2011, 86(3): 1157-1166. PARKA I K, TRANA T H, OHA I H, et al. Ternary biomolecular nanoparticles for targeting of cancer cells and anti-angiogenesis . Eur. J Pharmaceutical Sci, 2010, 41(1): 148-155. WANG X, LI J, WANG Y, et al. HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors . ACSNANO, 2009, 3(10): 3165-3174. WANG X, LI J, WANG Y, et al. A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model . ACSNANO, 2011, 5(8): 6184-6194. LI L, HUH K M, LEE Y K, et al. Biofunctional self-assembled nanoparticles of folate-PEG-heparin/PBLA copolymers for targeted delivery of doxorubicin. J Mater Chem, 2011, 21(39): 15288-15297 . LI L, MOON H T, PARK J Y, et al. Heparin-based self-assembled nanoparticles for photodynamic therapy . Macromolecular Res, 2011, 19(5) 487-494 . CHANG C H, HUANG W Y, LAI C H, et al. Development of novel nanoparticles shelled with heparin for berberine delivery to treat Helicobacter pylori . Acta Biomaterialia, 2011, 7(12): 593-603. BAE K H, MOK H, PARK T G. Synthesis, characterization, and intracellular delivery of reducible heparin nanogels for apoptotic cell death . Biomaterials, 2008, 29(23): 3376-3383.
2013, Vol. 48 
